Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, ...

We recently published 10 Firms in the Limelight. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best performers on Friday. Amicus Therapeutics soared to a new 52-week high on Friday, jumping 30 ...

Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases. The drugmaker ...

Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN.O), opens new tab said on Friday it would acquire Amicus Therapeutics (FOLD.O), opens new tab for about $4.8 billion, in the drugmaker's second deal ...

BioMarin Pharmaceutical (BMRN) has agreed to acquire rare disease drug developer Amicus Therapeutics (FOLD) in an all-cash transaction worth nearly $4.8B, the companies announced on Friday. The deal, ...

Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus Therapeutics, a company whose two commercialized products each offer ...

The Nevada attorney general’s office has filed a “friend of the court” brief on behalf of the state of Maryland in its continuing battle against prediction markets that are taking sports bets the ...

・The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday. ・Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin ...

Sixteen months after luring former Roche dealmaker James Sabry, M.D., Ph.D., out of retirement and signaling a shift in its business development approach, BioMarin has announced the largest ...

The all-cash acquisition price translates to $14.50 per share, valuing the offer at a 33% premium to Amicus's last close, a 46% premium to its 30-day average price, and a 58% premium to its 60-day ...

SAN RAFAEL, Calif., and PRINCETON, N.J., Dec. 19, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into ...